nodes	percent_of_prediction	percent_of_DWPC	metapath
Trabectedin—Alkylating Activity—Temozolomide—skin cancer	0.42	0.556	CiPCiCtD
Trabectedin—Alkylating Activity—Dacarbazine—skin cancer	0.336	0.444	CiPCiCtD
Trabectedin—CYP2C19—Vismodegib—skin cancer	0.0266	0.164	CbGbCtD
Trabectedin—CYP2E1—Dacarbazine—skin cancer	0.0257	0.159	CbGbCtD
Trabectedin—CYP2C9—Vismodegib—skin cancer	0.0221	0.137	CbGbCtD
Trabectedin—CYP3A4—Temozolomide—skin cancer	0.0185	0.115	CbGbCtD
Trabectedin—CYP3A4—Imiquimod—skin cancer	0.0185	0.115	CbGbCtD
Trabectedin—CYP2D6—Vemurafenib—skin cancer	0.016	0.0987	CbGbCtD
Trabectedin—CYP3A4—Vismodegib—skin cancer	0.0129	0.0794	CbGbCtD
Trabectedin—CYP3A4—Vemurafenib—skin cancer	0.0102	0.0628	CbGbCtD
Trabectedin—CYP2C9—Fluorouracil—skin cancer	0.00785	0.0485	CbGbCtD
Trabectedin—CYP3A4—Docetaxel—skin cancer	0.00349	0.0215	CbGbCtD
Trabectedin—SRC—endothelium—skin cancer	0.000499	0.14	CbGeAlD
Trabectedin—SRC—blood vessel—skin cancer	0.00046	0.129	CbGeAlD
Trabectedin—SRC—connective tissue—skin cancer	0.000236	0.0662	CbGeAlD
Trabectedin—SRC—epithelium—skin cancer	0.000224	0.0629	CbGeAlD
Trabectedin—SRC—skin of body—skin cancer	0.000213	0.0598	CbGeAlD
Trabectedin—PTGS1—endothelium—skin cancer	0.000186	0.0523	CbGeAlD
Trabectedin—Syncope—Imiquimod—skin cancer	0.000181	0.00257	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.000181	0.00256	CcSEcCtD
Trabectedin—Hypotension—Vemurafenib—skin cancer	0.00018	0.00256	CcSEcCtD
Trabectedin—Neutropenia—Dactinomycin—skin cancer	0.000179	0.00254	CcSEcCtD
Trabectedin—Stomatitis—Bleomycin—skin cancer	0.000179	0.00253	CcSEcCtD
Trabectedin—Loss of consciousness—Imiquimod—skin cancer	0.000177	0.00251	CcSEcCtD
Trabectedin—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000177	0.00251	CcSEcCtD
Trabectedin—Cough—Imiquimod—skin cancer	0.000176	0.0025	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000176	0.00249	CcSEcCtD
Trabectedin—SRC—lymphoid tissue—skin cancer	0.000173	0.0484	CbGeAlD
Trabectedin—PTGS1—blood vessel—skin cancer	0.000172	0.0482	CbGeAlD
Trabectedin—Myalgia—Imiquimod—skin cancer	0.000172	0.00244	CcSEcCtD
Trabectedin—Arthralgia—Imiquimod—skin cancer	0.000172	0.00244	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000171	0.00242	CcSEcCtD
Trabectedin—Decreased appetite—Vemurafenib—skin cancer	0.000168	0.00238	CcSEcCtD
Trabectedin—Stomatitis—Dactinomycin—skin cancer	0.000167	0.00236	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000167	0.00236	CcSEcCtD
Trabectedin—SRC—female reproductive system—skin cancer	0.000167	0.0467	CbGeAlD
Trabectedin—Fatigue—Vemurafenib—skin cancer	0.000166	0.00236	CcSEcCtD
Trabectedin—Haemoglobin—Bleomycin—skin cancer	0.000165	0.00235	CcSEcCtD
Trabectedin—Constipation—Vemurafenib—skin cancer	0.000165	0.00234	CcSEcCtD
Trabectedin—Pancytopenia—Temozolomide—skin cancer	0.000165	0.00234	CcSEcCtD
Trabectedin—Oedema—Imiquimod—skin cancer	0.000165	0.00233	CcSEcCtD
Trabectedin—Haemorrhage—Bleomycin—skin cancer	0.000165	0.00233	CcSEcCtD
Trabectedin—Pulmonary oedema—Docetaxel—skin cancer	0.000164	0.00232	CcSEcCtD
Trabectedin—Infection—Imiquimod—skin cancer	0.000164	0.00232	CcSEcCtD
Trabectedin—Neutropenia—Temozolomide—skin cancer	0.000162	0.0023	CcSEcCtD
Trabectedin—Shock—Imiquimod—skin cancer	0.000162	0.0023	CcSEcCtD
Trabectedin—Nervous system disorder—Imiquimod—skin cancer	0.000161	0.00229	CcSEcCtD
Trabectedin—Skin disorder—Imiquimod—skin cancer	0.00016	0.00227	CcSEcCtD
Trabectedin—Agranulocytosis—Dactinomycin—skin cancer	0.00016	0.00226	CcSEcCtD
Trabectedin—Sepsis—Docetaxel—skin cancer	0.00016	0.00226	CcSEcCtD
Trabectedin—Weight decreased—Temozolomide—skin cancer	0.000157	0.00223	CcSEcCtD
Trabectedin—Anorexia—Imiquimod—skin cancer	0.000157	0.00223	CcSEcCtD
Trabectedin—Infestation NOS—Temozolomide—skin cancer	0.000155	0.00219	CcSEcCtD
Trabectedin—Infestation—Temozolomide—skin cancer	0.000155	0.00219	CcSEcCtD
Trabectedin—Blood alkaline phosphatase increased—Docetaxel—skin cancer	0.000153	0.00218	CcSEcCtD
Trabectedin—Flushing—Bleomycin—skin cancer	0.000153	0.00217	CcSEcCtD
Trabectedin—Body temperature increased—Vemurafenib—skin cancer	0.000153	0.00216	CcSEcCtD
Trabectedin—Pancytopenia—Fluorouracil—skin cancer	0.000152	0.00215	CcSEcCtD
Trabectedin—Stomatitis—Temozolomide—skin cancer	0.000151	0.00214	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00015	0.00213	CcSEcCtD
Trabectedin—Insomnia—Imiquimod—skin cancer	0.000149	0.00211	CcSEcCtD
Trabectedin—Hepatic failure—Docetaxel—skin cancer	0.000149	0.00211	CcSEcCtD
Trabectedin—Paraesthesia—Imiquimod—skin cancer	0.000148	0.0021	CcSEcCtD
Trabectedin—Dyspnoea—Imiquimod—skin cancer	0.000147	0.00208	CcSEcCtD
Trabectedin—Hepatobiliary disease—Temozolomide—skin cancer	0.000146	0.00207	CcSEcCtD
Trabectedin—Alopecia—Bleomycin—skin cancer	0.000145	0.00206	CcSEcCtD
Trabectedin—Dyspepsia—Imiquimod—skin cancer	0.000145	0.00206	CcSEcCtD
Trabectedin—Decreased appetite—Imiquimod—skin cancer	0.000143	0.00203	CcSEcCtD
Trabectedin—Infestation NOS—Fluorouracil—skin cancer	0.000143	0.00202	CcSEcCtD
Trabectedin—Infestation—Fluorouracil—skin cancer	0.000143	0.00202	CcSEcCtD
Trabectedin—Flushing—Dactinomycin—skin cancer	0.000143	0.00202	CcSEcCtD
Trabectedin—Hypersensitivity—Vemurafenib—skin cancer	0.000142	0.00202	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Imiquimod—skin cancer	0.000142	0.00202	CcSEcCtD
Trabectedin—Fatigue—Imiquimod—skin cancer	0.000142	0.00201	CcSEcCtD
Trabectedin—Haemoglobin—Temozolomide—skin cancer	0.00014	0.00198	CcSEcCtD
Trabectedin—SRC—head—skin cancer	0.000139	0.039	CbGeAlD
Trabectedin—Stomatitis—Fluorouracil—skin cancer	0.000139	0.00197	CcSEcCtD
Trabectedin—Haemorrhage—Temozolomide—skin cancer	0.000139	0.00197	CcSEcCtD
Trabectedin—Asthenia—Vemurafenib—skin cancer	0.000139	0.00196	CcSEcCtD
Trabectedin—Oedema peripheral—Temozolomide—skin cancer	0.000137	0.00194	CcSEcCtD
Trabectedin—Connective tissue disorder—Temozolomide—skin cancer	0.000136	0.00194	CcSEcCtD
Trabectedin—Alopecia—Dactinomycin—skin cancer	0.000136	0.00192	CcSEcCtD
Trabectedin—Gastrointestinal pain—Imiquimod—skin cancer	0.000135	0.00191	CcSEcCtD
Trabectedin—Agranulocytosis—Fluorouracil—skin cancer	0.000133	0.00189	CcSEcCtD
Trabectedin—Anaemia—Bleomycin—skin cancer	0.000132	0.00188	CcSEcCtD
Trabectedin—Diarrhoea—Vemurafenib—skin cancer	0.000132	0.00187	CcSEcCtD
Trabectedin—Abdominal pain—Imiquimod—skin cancer	0.00013	0.00185	CcSEcCtD
Trabectedin—Body temperature increased—Imiquimod—skin cancer	0.00013	0.00185	CcSEcCtD
Trabectedin—Flushing—Temozolomide—skin cancer	0.000129	0.00183	CcSEcCtD
Trabectedin—Haemoglobin—Fluorouracil—skin cancer	0.000129	0.00182	CcSEcCtD
Trabectedin—Leukopenia—Bleomycin—skin cancer	0.000128	0.00182	CcSEcCtD
Trabectedin—Haemorrhage—Fluorouracil—skin cancer	0.000128	0.00181	CcSEcCtD
Trabectedin—Dizziness—Vemurafenib—skin cancer	0.000128	0.00181	CcSEcCtD
Trabectedin—Angiopathy—Temozolomide—skin cancer	0.000126	0.00179	CcSEcCtD
Trabectedin—Mediastinal disorder—Temozolomide—skin cancer	0.000125	0.00177	CcSEcCtD
Trabectedin—Cough—Bleomycin—skin cancer	0.000125	0.00177	CcSEcCtD
Trabectedin—PTGS1—nipple—skin cancer	0.000124	0.0349	CbGeAlD
Trabectedin—Dehydration—Docetaxel—skin cancer	0.000124	0.00176	CcSEcCtD
Trabectedin—Anaemia—Dactinomycin—skin cancer	0.000124	0.00175	CcSEcCtD
Trabectedin—Vomiting—Vemurafenib—skin cancer	0.000123	0.00174	CcSEcCtD
Trabectedin—Alopecia—Temozolomide—skin cancer	0.000123	0.00174	CcSEcCtD
Trabectedin—Myalgia—Bleomycin—skin cancer	0.000122	0.00173	CcSEcCtD
Trabectedin—Abdominal pain upper—Docetaxel—skin cancer	0.000122	0.00173	CcSEcCtD
Trabectedin—Rash—Vemurafenib—skin cancer	0.000122	0.00173	CcSEcCtD
Trabectedin—Mental disorder—Temozolomide—skin cancer	0.000122	0.00173	CcSEcCtD
Trabectedin—Dermatitis—Vemurafenib—skin cancer	0.000122	0.00172	CcSEcCtD
Trabectedin—Hypersensitivity—Imiquimod—skin cancer	0.000121	0.00172	CcSEcCtD
Trabectedin—Headache—Vemurafenib—skin cancer	0.000121	0.00172	CcSEcCtD
Trabectedin—Malnutrition—Temozolomide—skin cancer	0.000121	0.00171	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.00012	0.0017	CcSEcCtD
Trabectedin—Leukopenia—Dactinomycin—skin cancer	0.00012	0.0017	CcSEcCtD
Trabectedin—Dysgeusia—Temozolomide—skin cancer	0.000118	0.00168	CcSEcCtD
Trabectedin—Asthenia—Imiquimod—skin cancer	0.000118	0.00168	CcSEcCtD
Trabectedin—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000118	0.00167	CcSEcCtD
Trabectedin—Oedema—Bleomycin—skin cancer	0.000117	0.00166	CcSEcCtD
Trabectedin—Back pain—Temozolomide—skin cancer	0.000117	0.00166	CcSEcCtD
Trabectedin—Infection—Bleomycin—skin cancer	0.000116	0.00165	CcSEcCtD
Trabectedin—Nausea—Vemurafenib—skin cancer	0.000115	0.00163	CcSEcCtD
Trabectedin—Thrombocytopenia—Bleomycin—skin cancer	0.000115	0.00162	CcSEcCtD
Trabectedin—Myalgia—Dactinomycin—skin cancer	0.000114	0.00161	CcSEcCtD
Trabectedin—Alopecia—Fluorouracil—skin cancer	0.000113	0.0016	CcSEcCtD
Trabectedin—Diarrhoea—Imiquimod—skin cancer	0.000113	0.0016	CcSEcCtD
Trabectedin—Anaemia—Temozolomide—skin cancer	0.000112	0.00158	CcSEcCtD
Trabectedin—Anorexia—Bleomycin—skin cancer	0.000112	0.00158	CcSEcCtD
Trabectedin—Pancytopenia—Docetaxel—skin cancer	0.00011	0.00155	CcSEcCtD
Trabectedin—Hypotension—Bleomycin—skin cancer	0.000109	0.00155	CcSEcCtD
Trabectedin—Oedema—Dactinomycin—skin cancer	0.000109	0.00155	CcSEcCtD
Trabectedin—Dizziness—Imiquimod—skin cancer	0.000109	0.00154	CcSEcCtD
Trabectedin—Infection—Dactinomycin—skin cancer	0.000108	0.00154	CcSEcCtD
Trabectedin—Leukopenia—Temozolomide—skin cancer	0.000108	0.00153	CcSEcCtD
Trabectedin—Neutropenia—Docetaxel—skin cancer	0.000108	0.00153	CcSEcCtD
Trabectedin—Thrombocytopenia—Dactinomycin—skin cancer	0.000107	0.00151	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000107	0.00151	CcSEcCtD
Trabectedin—Cough—Temozolomide—skin cancer	0.000106	0.0015	CcSEcCtD
Trabectedin—Paraesthesia—Bleomycin—skin cancer	0.000105	0.00149	CcSEcCtD
Trabectedin—Vomiting—Imiquimod—skin cancer	0.000105	0.00148	CcSEcCtD
Trabectedin—Weight decreased—Docetaxel—skin cancer	0.000104	0.00148	CcSEcCtD
Trabectedin—Dyspnoea—Bleomycin—skin cancer	0.000104	0.00148	CcSEcCtD
Trabectedin—Anorexia—Dactinomycin—skin cancer	0.000104	0.00147	CcSEcCtD
Trabectedin—Rash—Imiquimod—skin cancer	0.000104	0.00147	CcSEcCtD
Trabectedin—Dermatitis—Imiquimod—skin cancer	0.000104	0.00147	CcSEcCtD
Trabectedin—Headache—Imiquimod—skin cancer	0.000103	0.00146	CcSEcCtD
Trabectedin—Anaemia—Fluorouracil—skin cancer	0.000103	0.00146	CcSEcCtD
Trabectedin—Arthralgia—Temozolomide—skin cancer	0.000103	0.00146	CcSEcCtD
Trabectedin—Myalgia—Temozolomide—skin cancer	0.000103	0.00146	CcSEcCtD
Trabectedin—Infestation NOS—Docetaxel—skin cancer	0.000103	0.00146	CcSEcCtD
Trabectedin—Infestation—Docetaxel—skin cancer	0.000103	0.00146	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000102	0.00145	CcSEcCtD
Trabectedin—Decreased appetite—Bleomycin—skin cancer	0.000102	0.00144	CcSEcCtD
Trabectedin—Stomatitis—Docetaxel—skin cancer	0.0001	0.00142	CcSEcCtD
Trabectedin—Jaundice—Docetaxel—skin cancer	0.0001	0.00142	CcSEcCtD
Trabectedin—Leukopenia—Fluorouracil—skin cancer	9.97e-05	0.00141	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Dactinomycin—skin cancer	9.94e-05	0.00141	CcSEcCtD
Trabectedin—Oedema—Temozolomide—skin cancer	9.87e-05	0.0014	CcSEcCtD
Trabectedin—Infection—Temozolomide—skin cancer	9.8e-05	0.00139	CcSEcCtD
Trabectedin—Nausea—Imiquimod—skin cancer	9.78e-05	0.00139	CcSEcCtD
Trabectedin—SRC—lymph node—skin cancer	9.74e-05	0.0273	CbGeAlD
Trabectedin—Hepatobiliary disease—Docetaxel—skin cancer	9.73e-05	0.00138	CcSEcCtD
Trabectedin—Nervous system disorder—Temozolomide—skin cancer	9.68e-05	0.00137	CcSEcCtD
Trabectedin—Thrombocytopenia—Temozolomide—skin cancer	9.66e-05	0.00137	CcSEcCtD
Trabectedin—Agranulocytosis—Docetaxel—skin cancer	9.6e-05	0.00136	CcSEcCtD
Trabectedin—Skin disorder—Temozolomide—skin cancer	9.58e-05	0.00136	CcSEcCtD
Trabectedin—Myalgia—Fluorouracil—skin cancer	9.48e-05	0.00134	CcSEcCtD
Trabectedin—Decreased appetite—Dactinomycin—skin cancer	9.48e-05	0.00134	CcSEcCtD
Trabectedin—Fatigue—Dactinomycin—skin cancer	9.41e-05	0.00133	CcSEcCtD
Trabectedin—Anorexia—Temozolomide—skin cancer	9.41e-05	0.00133	CcSEcCtD
Trabectedin—Haemoglobin—Docetaxel—skin cancer	9.28e-05	0.00132	CcSEcCtD
Trabectedin—Body temperature increased—Bleomycin—skin cancer	9.25e-05	0.00131	CcSEcCtD
Trabectedin—Haemorrhage—Docetaxel—skin cancer	9.24e-05	0.00131	CcSEcCtD
Trabectedin—Oedema peripheral—Docetaxel—skin cancer	9.1e-05	0.00129	CcSEcCtD
Trabectedin—Oedema—Fluorouracil—skin cancer	9.09e-05	0.00129	CcSEcCtD
Trabectedin—Connective tissue disorder—Docetaxel—skin cancer	9.08e-05	0.00129	CcSEcCtD
Trabectedin—Infection—Fluorouracil—skin cancer	9.03e-05	0.00128	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Temozolomide—skin cancer	8.99e-05	0.00127	CcSEcCtD
Trabectedin—Insomnia—Temozolomide—skin cancer	8.92e-05	0.00127	CcSEcCtD
Trabectedin—Gastrointestinal pain—Dactinomycin—skin cancer	8.92e-05	0.00126	CcSEcCtD
Trabectedin—Nervous system disorder—Fluorouracil—skin cancer	8.92e-05	0.00126	CcSEcCtD
Trabectedin—Thrombocytopenia—Fluorouracil—skin cancer	8.9e-05	0.00126	CcSEcCtD
Trabectedin—Paraesthesia—Temozolomide—skin cancer	8.86e-05	0.00126	CcSEcCtD
Trabectedin—PTGS1—connective tissue—skin cancer	8.81e-05	0.0247	CbGeAlD
Trabectedin—Dyspnoea—Temozolomide—skin cancer	8.8e-05	0.00125	CcSEcCtD
Trabectedin—Dyspepsia—Temozolomide—skin cancer	8.69e-05	0.00123	CcSEcCtD
Trabectedin—Anorexia—Fluorouracil—skin cancer	8.67e-05	0.00123	CcSEcCtD
Trabectedin—Abdominal pain—Dactinomycin—skin cancer	8.62e-05	0.00122	CcSEcCtD
Trabectedin—Body temperature increased—Dactinomycin—skin cancer	8.62e-05	0.00122	CcSEcCtD
Trabectedin—Hypersensitivity—Bleomycin—skin cancer	8.62e-05	0.00122	CcSEcCtD
Trabectedin—Decreased appetite—Temozolomide—skin cancer	8.58e-05	0.00122	CcSEcCtD
Trabectedin—Flushing—Docetaxel—skin cancer	8.57e-05	0.00122	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Temozolomide—skin cancer	8.52e-05	0.00121	CcSEcCtD
Trabectedin—Fatigue—Temozolomide—skin cancer	8.51e-05	0.00121	CcSEcCtD
Trabectedin—Hypotension—Fluorouracil—skin cancer	8.5e-05	0.0012	CcSEcCtD
Trabectedin—Constipation—Temozolomide—skin cancer	8.44e-05	0.0012	CcSEcCtD
Trabectedin—Asthenia—Bleomycin—skin cancer	8.39e-05	0.00119	CcSEcCtD
Trabectedin—Angiopathy—Docetaxel—skin cancer	8.38e-05	0.00119	CcSEcCtD
Trabectedin—PTGS1—epithelium—skin cancer	8.37e-05	0.0235	CbGeAlD
Trabectedin—Mediastinal disorder—Docetaxel—skin cancer	8.32e-05	0.00118	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Fluorouracil—skin cancer	8.28e-05	0.00117	CcSEcCtD
Trabectedin—Insomnia—Fluorouracil—skin cancer	8.22e-05	0.00117	CcSEcCtD
Trabectedin—Paraesthesia—Fluorouracil—skin cancer	8.16e-05	0.00116	CcSEcCtD
Trabectedin—Alopecia—Docetaxel—skin cancer	8.16e-05	0.00116	CcSEcCtD
Trabectedin—Dyspnoea—Fluorouracil—skin cancer	8.11e-05	0.00115	CcSEcCtD
Trabectedin—Mental disorder—Docetaxel—skin cancer	8.09e-05	0.00115	CcSEcCtD
Trabectedin—Gastrointestinal pain—Temozolomide—skin cancer	8.07e-05	0.00114	CcSEcCtD
Trabectedin—Malnutrition—Docetaxel—skin cancer	8.04e-05	0.00114	CcSEcCtD
Trabectedin—Hypersensitivity—Dactinomycin—skin cancer	8.04e-05	0.00114	CcSEcCtD
Trabectedin—Dyspepsia—Fluorouracil—skin cancer	8e-05	0.00113	CcSEcCtD
Trabectedin—PTGS1—skin of body—skin cancer	7.96e-05	0.0223	CbGeAlD
Trabectedin—Decreased appetite—Fluorouracil—skin cancer	7.9e-05	0.00112	CcSEcCtD
Trabectedin—Dysgeusia—Docetaxel—skin cancer	7.87e-05	0.00112	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Fluorouracil—skin cancer	7.85e-05	0.00111	CcSEcCtD
Trabectedin—Asthenia—Dactinomycin—skin cancer	7.83e-05	0.00111	CcSEcCtD
Trabectedin—Body temperature increased—Temozolomide—skin cancer	7.8e-05	0.00111	CcSEcCtD
Trabectedin—Abdominal pain—Temozolomide—skin cancer	7.8e-05	0.00111	CcSEcCtD
Trabectedin—Back pain—Docetaxel—skin cancer	7.78e-05	0.0011	CcSEcCtD
Trabectedin—Diarrhoea—Dactinomycin—skin cancer	7.46e-05	0.00106	CcSEcCtD
Trabectedin—Vomiting—Bleomycin—skin cancer	7.44e-05	0.00105	CcSEcCtD
Trabectedin—Anaemia—Docetaxel—skin cancer	7.43e-05	0.00105	CcSEcCtD
Trabectedin—Rash—Bleomycin—skin cancer	7.38e-05	0.00105	CcSEcCtD
Trabectedin—Dermatitis—Bleomycin—skin cancer	7.37e-05	0.00104	CcSEcCtD
Trabectedin—Hypersensitivity—Temozolomide—skin cancer	7.27e-05	0.00103	CcSEcCtD
Trabectedin—PTGS1—mammalian vulva—skin cancer	7.26e-05	0.0204	CbGeAlD
Trabectedin—Syncope—Docetaxel—skin cancer	7.21e-05	0.00102	CcSEcCtD
Trabectedin—Leukopenia—Docetaxel—skin cancer	7.2e-05	0.00102	CcSEcCtD
Trabectedin—Body temperature increased—Fluorouracil—skin cancer	7.19e-05	0.00102	CcSEcCtD
Trabectedin—Asthenia—Temozolomide—skin cancer	7.08e-05	0.001	CcSEcCtD
Trabectedin—Loss of consciousness—Docetaxel—skin cancer	7.07e-05	0.001	CcSEcCtD
Trabectedin—Cough—Docetaxel—skin cancer	7.02e-05	0.000995	CcSEcCtD
Trabectedin—Nausea—Bleomycin—skin cancer	6.95e-05	0.000985	CcSEcCtD
Trabectedin—Vomiting—Dactinomycin—skin cancer	6.94e-05	0.000984	CcSEcCtD
Trabectedin—Rash—Dactinomycin—skin cancer	6.88e-05	0.000975	CcSEcCtD
Trabectedin—Arthralgia—Docetaxel—skin cancer	6.85e-05	0.000971	CcSEcCtD
Trabectedin—Myalgia—Docetaxel—skin cancer	6.85e-05	0.000971	CcSEcCtD
Trabectedin—CYP2C9—female reproductive system—skin cancer	6.81e-05	0.0191	CbGeAlD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	6.8e-05	0.000964	CcSEcCtD
Trabectedin—Diarrhoea—Temozolomide—skin cancer	6.75e-05	0.000957	CcSEcCtD
Trabectedin—Hypersensitivity—Fluorouracil—skin cancer	6.7e-05	0.00095	CcSEcCtD
Trabectedin—CYP2E1—lymphoid tissue—skin cancer	6.69e-05	0.0188	CbGeAlD
Trabectedin—Oedema—Docetaxel—skin cancer	6.56e-05	0.00093	CcSEcCtD
Trabectedin—Dizziness—Temozolomide—skin cancer	6.53e-05	0.000925	CcSEcCtD
Trabectedin—Infection—Docetaxel—skin cancer	6.52e-05	0.000924	CcSEcCtD
Trabectedin—Nausea—Dactinomycin—skin cancer	6.48e-05	0.000919	CcSEcCtD
Trabectedin—Shock—Docetaxel—skin cancer	6.46e-05	0.000915	CcSEcCtD
Trabectedin—CYP2E1—female reproductive system—skin cancer	6.45e-05	0.0181	CbGeAlD
Trabectedin—Nervous system disorder—Docetaxel—skin cancer	6.44e-05	0.000912	CcSEcCtD
Trabectedin—Thrombocytopenia—Docetaxel—skin cancer	6.42e-05	0.000911	CcSEcCtD
Trabectedin—Skin disorder—Docetaxel—skin cancer	6.37e-05	0.000904	CcSEcCtD
Trabectedin—Vomiting—Temozolomide—skin cancer	6.27e-05	0.00089	CcSEcCtD
Trabectedin—Anorexia—Docetaxel—skin cancer	6.25e-05	0.000887	CcSEcCtD
Trabectedin—Rash—Temozolomide—skin cancer	6.22e-05	0.000882	CcSEcCtD
Trabectedin—Diarrhoea—Fluorouracil—skin cancer	6.22e-05	0.000882	CcSEcCtD
Trabectedin—Dermatitis—Temozolomide—skin cancer	6.22e-05	0.000881	CcSEcCtD
Trabectedin—PTGS1—female reproductive system—skin cancer	6.21e-05	0.0174	CbGeAlD
Trabectedin—Headache—Temozolomide—skin cancer	6.18e-05	0.000877	CcSEcCtD
Trabectedin—Hypotension—Docetaxel—skin cancer	6.13e-05	0.000869	CcSEcCtD
Trabectedin—Dizziness—Fluorouracil—skin cancer	6.01e-05	0.000852	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Docetaxel—skin cancer	5.98e-05	0.000848	CcSEcCtD
Trabectedin—Insomnia—Docetaxel—skin cancer	5.93e-05	0.000842	CcSEcCtD
Trabectedin—Paraesthesia—Docetaxel—skin cancer	5.89e-05	0.000836	CcSEcCtD
Trabectedin—Nausea—Temozolomide—skin cancer	5.86e-05	0.000831	CcSEcCtD
Trabectedin—Dyspnoea—Docetaxel—skin cancer	5.85e-05	0.00083	CcSEcCtD
Trabectedin—Vomiting—Fluorouracil—skin cancer	5.78e-05	0.00082	CcSEcCtD
Trabectedin—Dyspepsia—Docetaxel—skin cancer	5.78e-05	0.000819	CcSEcCtD
Trabectedin—Rash—Fluorouracil—skin cancer	5.73e-05	0.000813	CcSEcCtD
Trabectedin—Dermatitis—Fluorouracil—skin cancer	5.73e-05	0.000812	CcSEcCtD
Trabectedin—Decreased appetite—Docetaxel—skin cancer	5.7e-05	0.000809	CcSEcCtD
Trabectedin—Headache—Fluorouracil—skin cancer	5.7e-05	0.000808	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Docetaxel—skin cancer	5.67e-05	0.000803	CcSEcCtD
Trabectedin—Fatigue—Docetaxel—skin cancer	5.66e-05	0.000802	CcSEcCtD
Trabectedin—Constipation—Docetaxel—skin cancer	5.61e-05	0.000796	CcSEcCtD
Trabectedin—Nausea—Fluorouracil—skin cancer	5.4e-05	0.000766	CcSEcCtD
Trabectedin—CYP2E1—head—skin cancer	5.39e-05	0.0151	CbGeAlD
Trabectedin—Gastrointestinal pain—Docetaxel—skin cancer	5.37e-05	0.000761	CcSEcCtD
Trabectedin—PTGS1—head—skin cancer	5.19e-05	0.0146	CbGeAlD
Trabectedin—CYP3A4—female reproductive system—skin cancer	5.19e-05	0.0146	CbGeAlD
Trabectedin—Abdominal pain—Docetaxel—skin cancer	5.19e-05	0.000736	CcSEcCtD
Trabectedin—Body temperature increased—Docetaxel—skin cancer	5.19e-05	0.000736	CcSEcCtD
Trabectedin—CYP2D6—female reproductive system—skin cancer	5.11e-05	0.0143	CbGeAlD
Trabectedin—Hypersensitivity—Docetaxel—skin cancer	4.83e-05	0.000686	CcSEcCtD
Trabectedin—Asthenia—Docetaxel—skin cancer	4.71e-05	0.000668	CcSEcCtD
Trabectedin—Diarrhoea—Docetaxel—skin cancer	4.49e-05	0.000637	CcSEcCtD
Trabectedin—Dizziness—Docetaxel—skin cancer	4.34e-05	0.000615	CcSEcCtD
Trabectedin—CYP2D6—head—skin cancer	4.27e-05	0.012	CbGeAlD
Trabectedin—Vomiting—Docetaxel—skin cancer	4.17e-05	0.000592	CcSEcCtD
Trabectedin—Rash—Docetaxel—skin cancer	4.14e-05	0.000587	CcSEcCtD
Trabectedin—Dermatitis—Docetaxel—skin cancer	4.13e-05	0.000586	CcSEcCtD
Trabectedin—Headache—Docetaxel—skin cancer	4.11e-05	0.000583	CcSEcCtD
Trabectedin—Nausea—Docetaxel—skin cancer	3.9e-05	0.000553	CcSEcCtD
Trabectedin—PTGS1—lymph node—skin cancer	3.64e-05	0.0102	CbGeAlD
Trabectedin—SRC—Nongenotropic Androgen signaling—HRAS—skin cancer	3.38e-05	0.00398	CbGpPWpGaD
Trabectedin—SRC—Internalization of ErbB1—KRAS—skin cancer	3.38e-05	0.00398	CbGpPWpGaD
Trabectedin—SRC—CXCR3-mediated signaling events—KRAS—skin cancer	3.38e-05	0.00398	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—BRAF—skin cancer	3.38e-05	0.00397	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—FOXO4—skin cancer	3.37e-05	0.00397	CbGpPWpGaD
Trabectedin—SRC—Aryl Hydrocarbon Receptor—NRAS—skin cancer	3.37e-05	0.00396	CbGpPWpGaD
Trabectedin—SRC—EPHB forward signaling—KRAS—skin cancer	3.31e-05	0.00389	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—SCN10A—skin cancer	3.22e-05	0.00379	CbGpPWpGaD
Trabectedin—SRC—Alpha 6 Beta 4 signaling pathway—HRAS—skin cancer	3.22e-05	0.00378	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	3.19e-05	0.00375	CbGpPWpGaD
Trabectedin—SRC—Plasma membrane estrogen receptor signaling—KRAS—skin cancer	3.18e-05	0.00374	CbGpPWpGaD
Trabectedin—SRC—ErbB2/ErbB3 signaling events—KRAS—skin cancer	3.18e-05	0.00374	CbGpPWpGaD
Trabectedin—SRC—VEGFR2 mediated cell proliferation—HRAS—skin cancer	3.14e-05	0.00369	CbGpPWpGaD
Trabectedin—SRC—Signalling to RAS—HRAS—skin cancer	3.14e-05	0.00369	CbGpPWpGaD
Trabectedin—SRC—Signaling of Hepatocyte Growth Factor Receptor—HRAS—skin cancer	3.14e-05	0.00369	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—FOXO4—skin cancer	3.05e-05	0.00359	CbGpPWpGaD
Trabectedin—SRC—Signalling to ERKs—KRAS—skin cancer	3e-05	0.00354	CbGpPWpGaD
Trabectedin—SRC—Signalling to RAS—IL6—skin cancer	3e-05	0.00354	CbGpPWpGaD
Trabectedin—SRC—VEGFR2 mediated cell proliferation—IL6—skin cancer	3e-05	0.00354	CbGpPWpGaD
Trabectedin—SRC—Trk receptor signaling mediated by PI3K and PLC-gamma—HRAS—skin cancer	3e-05	0.00353	CbGpPWpGaD
Trabectedin—SRC—Syndecan-2-mediated signaling events—HRAS—skin cancer	3e-05	0.00353	CbGpPWpGaD
Trabectedin—SRC—Class I PI3K signaling events—KRAS—skin cancer	2.95e-05	0.00347	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—CDKN2A—skin cancer	2.92e-05	0.00343	CbGpPWpGaD
Trabectedin—SRC—TGF-beta Signaling Pathway—TERT—skin cancer	2.91e-05	0.00343	CbGpPWpGaD
Trabectedin—SRC—Aryl Hydrocarbon Receptor—KRAS—skin cancer	2.9e-05	0.00341	CbGpPWpGaD
Trabectedin—SRC—Integrin-mediated Cell Adhesion—BRAF—skin cancer	2.88e-05	0.00339	CbGpPWpGaD
Trabectedin—SRC—Internalization of ErbB1—HRAS—skin cancer	2.87e-05	0.00338	CbGpPWpGaD
Trabectedin—SRC—CXCR3-mediated signaling events—HRAS—skin cancer	2.87e-05	0.00338	CbGpPWpGaD
Trabectedin—SRC—EPHB forward signaling—HRAS—skin cancer	2.81e-05	0.00331	CbGpPWpGaD
Trabectedin—SRC—Signaling events regulated by Ret tyrosine kinase—HRAS—skin cancer	2.81e-05	0.00331	CbGpPWpGaD
Trabectedin—SRC—PDGF Pathway—HRAS—skin cancer	2.81e-05	0.00331	CbGpPWpGaD
Trabectedin—SRC—ErbB1 downstream signaling—BRAF—skin cancer	2.77e-05	0.00326	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—BRAF—skin cancer	2.77e-05	0.00326	CbGpPWpGaD
Trabectedin—PTGS1—Selenium Micronutrient Network—PTGS2—skin cancer	2.71e-05	0.00319	CbGpPWpGaD
Trabectedin—SRC—ErbB2/ErbB3 signaling events—HRAS—skin cancer	2.7e-05	0.00318	CbGpPWpGaD
Trabectedin—SRC—Plasma membrane estrogen receptor signaling—HRAS—skin cancer	2.7e-05	0.00318	CbGpPWpGaD
Trabectedin—SRC—EPHB-mediated forward signaling—HRAS—skin cancer	2.7e-05	0.00318	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—TLR7—skin cancer	2.6e-05	0.00306	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—RASA1—skin cancer	2.59e-05	0.00305	CbGpPWpGaD
Trabectedin—SRC—Interleukin-11 Signaling Pathway—HRAS—skin cancer	2.55e-05	0.00301	CbGpPWpGaD
Trabectedin—SRC—Signalling to ERKs—HRAS—skin cancer	2.55e-05	0.00301	CbGpPWpGaD
Trabectedin—SRC—ErbB Signaling Pathway—KRAS—skin cancer	2.55e-05	0.003	CbGpPWpGaD
Trabectedin—SRC—Class I PI3K signaling events—HRAS—skin cancer	2.51e-05	0.00295	CbGpPWpGaD
Trabectedin—SRC—Rac1/Pak1/p38/MMP-2 pathway—NRAS—skin cancer	2.49e-05	0.00293	CbGpPWpGaD
Trabectedin—SRC—Aryl Hydrocarbon Receptor—HRAS—skin cancer	2.46e-05	0.0029	CbGpPWpGaD
Trabectedin—SRC—NCAM signaling for neurite out-growth—NRAS—skin cancer	2.46e-05	0.0029	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—RHOU—skin cancer	2.46e-05	0.00289	CbGpPWpGaD
Trabectedin—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	2.46e-05	0.00289	CbGpPWpGaD
Trabectedin—SRC—Signalling to ERKs—IL6—skin cancer	2.44e-05	0.00288	CbGpPWpGaD
Trabectedin—SRC—PDGFR-beta signaling pathway—BRAF—skin cancer	2.41e-05	0.00283	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—CDKN2A—skin cancer	2.39e-05	0.00282	CbGpPWpGaD
Trabectedin—SRC—Posttranslational regulation of adherens junction stability and dissassembly—HRAS—skin cancer	2.38e-05	0.0028	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—FOXO4—skin cancer	2.35e-05	0.00276	CbGpPWpGaD
Trabectedin—SRC—IL-3 Signaling Pathway—HRAS—skin cancer	2.34e-05	0.00276	CbGpPWpGaD
Trabectedin—SRC—TSLP Signaling Pathway—IL6—skin cancer	2.32e-05	0.00273	CbGpPWpGaD
Trabectedin—SRC—ErbB Signaling Pathway—TP53—skin cancer	2.27e-05	0.00267	CbGpPWpGaD
Trabectedin—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	2.24e-05	0.00263	CbGpPWpGaD
Trabectedin—SRC—Oncostatin M Signaling Pathway—KRAS—skin cancer	2.2e-05	0.00259	CbGpPWpGaD
Trabectedin—SRC—ErbB Signaling Pathway—HRAS—skin cancer	2.17e-05	0.00255	CbGpPWpGaD
Trabectedin—SRC—Rac1/Pak1/p38/MMP-2 pathway—KRAS—skin cancer	2.15e-05	0.00253	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—NRAS—skin cancer	2.12e-05	0.0025	CbGpPWpGaD
Trabectedin—SRC—NCAM signaling for neurite out-growth—KRAS—skin cancer	2.12e-05	0.0025	CbGpPWpGaD
Trabectedin—SRC—Kit receptor signaling pathway—HRAS—skin cancer	2.02e-05	0.00238	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—BRAF—skin cancer	1.96e-05	0.0023	CbGpPWpGaD
Trabectedin—SRC—EGF/EGFR Signaling Pathway—BRAF—skin cancer	1.96e-05	0.0023	CbGpPWpGaD
Trabectedin—SRC—Oncostatin M Signaling Pathway—TP53—skin cancer	1.95e-05	0.0023	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.94e-05	0.00228	CbGpPWpGaD
Trabectedin—SRC—Endothelins—HRAS—skin cancer	1.92e-05	0.00225	CbGpPWpGaD
Trabectedin—SRC—Rac1/Pak1/p38/MMP-2 pathway—TP53—skin cancer	1.91e-05	0.00224	CbGpPWpGaD
Trabectedin—SRC—LPA receptor mediated events—HRAS—skin cancer	1.89e-05	0.00223	CbGpPWpGaD
Trabectedin—SRC—Oncostatin M Signaling Pathway—HRAS—skin cancer	1.87e-05	0.0022	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—RASA1—skin cancer	1.85e-05	0.00218	CbGpPWpGaD
Trabectedin—SRC—TSH signaling pathway—HRAS—skin cancer	1.85e-05	0.00217	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.84e-05	0.00216	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—KRAS—skin cancer	1.83e-05	0.00215	CbGpPWpGaD
Trabectedin—SRC—Cell surface interactions at the vascular wall—NRAS—skin cancer	1.82e-05	0.00215	CbGpPWpGaD
Trabectedin—SRC—Rac1/Pak1/p38/MMP-2 pathway—HRAS—skin cancer	1.82e-05	0.00215	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—BRAF—skin cancer	1.82e-05	0.00215	CbGpPWpGaD
Trabectedin—SRC—NCAM signaling for neurite out-growth—HRAS—skin cancer	1.8e-05	0.00212	CbGpPWpGaD
Trabectedin—SRC—CDC42 signaling events—HRAS—skin cancer	1.76e-05	0.00207	CbGpPWpGaD
Trabectedin—SRC—ErbB1 downstream signaling—NRAS—skin cancer	1.74e-05	0.00205	CbGpPWpGaD
Trabectedin—SRC—NCAM signaling for neurite out-growth—IL6—skin cancer	1.73e-05	0.00203	CbGpPWpGaD
Trabectedin—SRC—Focal Adhesion—BRAF—skin cancer	1.72e-05	0.00203	CbGpPWpGaD
Trabectedin—SRC—VEGFA-VEGFR2 Pathway—NRAS—skin cancer	1.71e-05	0.00202	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.68e-05	0.00197	CbGpPWpGaD
Trabectedin—SRC—Leptin signaling pathway—HRAS—skin cancer	1.67e-05	0.00196	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—TP53—skin cancer	1.62e-05	0.00191	CbGpPWpGaD
Trabectedin—SRC—Signaling by VEGF—NRAS—skin cancer	1.62e-05	0.0019	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	1.62e-05	0.0019	CbGpPWpGaD
Trabectedin—SRC—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—skin cancer	1.58e-05	0.00186	CbGpPWpGaD
Trabectedin—SRC—Cell surface interactions at the vascular wall—KRAS—skin cancer	1.57e-05	0.00185	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—HRAS—skin cancer	1.55e-05	0.00183	CbGpPWpGaD
Trabectedin—SRC—Immune System—TLR7—skin cancer	1.52e-05	0.00178	CbGpPWpGaD
Trabectedin—SRC—PDGFR-beta signaling pathway—NRAS—skin cancer	1.51e-05	0.00178	CbGpPWpGaD
Trabectedin—SRC—ErbB1 downstream signaling—KRAS—skin cancer	1.5e-05	0.00176	CbGpPWpGaD
Trabectedin—PTGS1—Selenium Micronutrient Network—IL6—skin cancer	1.48e-05	0.00174	CbGpPWpGaD
Trabectedin—SRC—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	1.48e-05	0.00174	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—PLIN2—skin cancer	1.42e-05	0.00167	CbGpPWpGaD
Trabectedin—SRC—Signaling by VEGF—KRAS—skin cancer	1.39e-05	0.00164	CbGpPWpGaD
Trabectedin—SRC—EPH-Ephrin signaling—HRAS—skin cancer	1.39e-05	0.00164	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	1.39e-05	0.00163	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—NRAS—skin cancer	1.38e-05	0.00162	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—FOXO4—skin cancer	1.34e-05	0.00158	CbGpPWpGaD
Trabectedin—SRC—Cell surface interactions at the vascular wall—HRAS—skin cancer	1.34e-05	0.00157	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—TP53—skin cancer	1.33e-05	0.00157	CbGpPWpGaD
Trabectedin—SRC—Integrin-mediated Cell Adhesion—HRAS—skin cancer	1.32e-05	0.00156	CbGpPWpGaD
Trabectedin—SRC—PDGFR-beta signaling pathway—KRAS—skin cancer	1.3e-05	0.00153	CbGpPWpGaD
Trabectedin—SRC—Disease—CSPG4—skin cancer	1.3e-05	0.00153	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—FOXO4—skin cancer	1.29e-05	0.00151	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—HRAS—skin cancer	1.27e-05	0.0015	CbGpPWpGaD
Trabectedin—SRC—ErbB1 downstream signaling—HRAS—skin cancer	1.27e-05	0.0015	CbGpPWpGaD
Trabectedin—SRC—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	1.25e-05	0.00148	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—BRAF—skin cancer	1.24e-05	0.00146	CbGpPWpGaD
Trabectedin—SRC—Downstream signal transduction—NRAS—skin cancer	1.24e-05	0.00146	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—NRAS—skin cancer	1.23e-05	0.00145	CbGpPWpGaD
Trabectedin—SRC—Signaling by ERBB2—NRAS—skin cancer	1.22e-05	0.00144	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—IL6—skin cancer	1.22e-05	0.00143	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—PTCH2—skin cancer	1.2e-05	0.00141	CbGpPWpGaD
Trabectedin—SRC—VEGFA-VEGFR2 Pathway—IL6—skin cancer	1.2e-05	0.00141	CbGpPWpGaD
Trabectedin—SRC—Signaling by VEGF—HRAS—skin cancer	1.18e-05	0.00139	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—KRAS—skin cancer	1.18e-05	0.00139	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—NRAS—skin cancer	1.15e-05	0.00135	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—CSPG4—skin cancer	1.14e-05	0.00135	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR—NRAS—skin cancer	1.14e-05	0.00134	CbGpPWpGaD
Trabectedin—SRC—Signaling by VEGF—IL6—skin cancer	1.13e-05	0.00133	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—NRAS—skin cancer	1.13e-05	0.00132	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—NRAS—skin cancer	1.12e-05	0.00132	CbGpPWpGaD
Trabectedin—SRC—TGF-beta Signaling Pathway—TP53—skin cancer	1.11e-05	0.0013	CbGpPWpGaD
Trabectedin—SRC—PDGFR-beta signaling pathway—HRAS—skin cancer	1.11e-05	0.0013	CbGpPWpGaD
Trabectedin—SRC—Downstream signal transduction—KRAS—skin cancer	1.06e-05	0.00125	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—PLIN2—skin cancer	1.06e-05	0.00125	CbGpPWpGaD
Trabectedin—SRC—EGF/EGFR Signaling Pathway—KRAS—skin cancer	1.06e-05	0.00125	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—KRAS—skin cancer	1.06e-05	0.00125	CbGpPWpGaD
Trabectedin—SRC—Signaling by ERBB2—KRAS—skin cancer	1.05e-05	0.00124	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	1.02e-05	0.00119	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—HRAS—skin cancer	1.01e-05	0.00118	CbGpPWpGaD
Trabectedin—SRC—BDNF signaling pathway—HRAS—skin cancer	9.89e-06	0.00116	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—KRAS—skin cancer	9.87e-06	0.00116	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR—KRAS—skin cancer	9.78e-06	0.00115	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—KRAS—skin cancer	9.69e-06	0.00114	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—KRAS—skin cancer	9.65e-06	0.00114	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—IL6—skin cancer	9.63e-06	0.00113	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	9.28e-06	0.00109	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—GLI2—skin cancer	9.11e-06	0.00107	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—CDK4—skin cancer	9.07e-06	0.00107	CbGpPWpGaD
Trabectedin—SRC—Downstream signal transduction—HRAS—skin cancer	9.05e-06	0.00106	CbGpPWpGaD
Trabectedin—SRC—EGF/EGFR Signaling Pathway—HRAS—skin cancer	9e-06	0.00106	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—HRAS—skin cancer	9e-06	0.00106	CbGpPWpGaD
Trabectedin—SRC—Signaling by ERBB2—HRAS—skin cancer	8.96e-06	0.00105	CbGpPWpGaD
Trabectedin—SRC—Disease—ENO2—skin cancer	8.84e-06	0.00104	CbGpPWpGaD
Trabectedin—SRC—Disease—SHH—skin cancer	8.84e-06	0.00104	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	8.74e-06	0.00103	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—MC1R—skin cancer	8.69e-06	0.00102	CbGpPWpGaD
Trabectedin—SRC—Downstream signal transduction—IL6—skin cancer	8.66e-06	0.00102	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—IL6—skin cancer	8.62e-06	0.00101	CbGpPWpGaD
Trabectedin—SRC—Signaling by ERBB2—IL6—skin cancer	8.57e-06	0.00101	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—GLI1—skin cancer	8.56e-06	0.00101	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—CSPG4—skin cancer	8.56e-06	0.00101	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—HRAS—skin cancer	8.39e-06	0.000987	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR—HRAS—skin cancer	8.31e-06	0.000978	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	8.25e-06	0.000971	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—HRAS—skin cancer	8.24e-06	0.000969	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—HRAS—skin cancer	8.2e-06	0.000965	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PLIN2—skin cancer	8.19e-06	0.000964	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—SUFU—skin cancer	8.12e-06	0.000955	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—IL6—skin cancer	8.03e-06	0.000944	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR—IL6—skin cancer	7.96e-06	0.000936	CbGpPWpGaD
Trabectedin—SRC—Focal Adhesion—HRAS—skin cancer	7.93e-06	0.000932	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—IL6—skin cancer	7.89e-06	0.000928	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—IL6—skin cancer	7.85e-06	0.000924	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—NRAS—skin cancer	7.81e-06	0.000919	CbGpPWpGaD
Trabectedin—SRC—Immune System—FOXO4—skin cancer	7.8e-06	0.000918	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—ENO2—skin cancer	7.78e-06	0.000916	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PLIN2—skin cancer	7.53e-06	0.000886	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PLIN2—skin cancer	7.47e-06	0.000879	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	7.43e-06	0.000874	CbGpPWpGaD
Trabectedin—SRC—Disease—FOXO4—skin cancer	7.21e-06	0.000848	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	7.11e-06	0.000837	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—NRAS—skin cancer	7.07e-06	0.000832	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—KRAS—skin cancer	6.72e-06	0.000791	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—CSPG4—skin cancer	6.6e-06	0.000777	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—SHH—skin cancer	6.19e-06	0.000728	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—RASA1—skin cancer	6.15e-06	0.000724	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.09e-06	0.000716	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—KRAS—skin cancer	6.08e-06	0.000716	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—CSPG4—skin cancer	6.07e-06	0.000714	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—CSPG4—skin cancer	6.02e-06	0.000708	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—PTCH1—skin cancer	5.87e-06	0.00069	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—SMO—skin cancer	5.87e-06	0.00069	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—ENO2—skin cancer	5.82e-06	0.000684	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—HRAS—skin cancer	5.71e-06	0.000672	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—PTGER4—skin cancer	5.71e-06	0.000672	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—IL6—skin cancer	5.47e-06	0.000643	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—HRAS—skin cancer	5.17e-06	0.000608	CbGpPWpGaD
Trabectedin—SRC—Disease—ERCC2—skin cancer	5.13e-06	0.000604	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—FOXO4—skin cancer	5.05e-06	0.000594	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—NRAS—skin cancer	5.04e-06	0.000593	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—IL6—skin cancer	4.95e-06	0.000582	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—NRAS—skin cancer	4.95e-06	0.000582	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PLIN2—skin cancer	4.92e-06	0.000579	CbGpPWpGaD
Trabectedin—SRC—Disease—TERT—skin cancer	4.81e-06	0.000566	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—ERCC2—skin cancer	4.52e-06	0.000532	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—ENO2—skin cancer	4.49e-06	0.000528	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—NRAS—skin cancer	4.45e-06	0.000524	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—KRAS—skin cancer	4.34e-06	0.000511	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—NRAS—skin cancer	4.28e-06	0.000503	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—KRAS—skin cancer	4.26e-06	0.000501	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—ENO2—skin cancer	4.13e-06	0.000486	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—ENO2—skin cancer	4.09e-06	0.000481	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—CSPG4—skin cancer	3.97e-06	0.000467	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—KRAS—skin cancer	3.83e-06	0.000451	CbGpPWpGaD
Trabectedin—SRC—Disease—BRAF—skin cancer	3.81e-06	0.000448	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—TP53—skin cancer	3.78e-06	0.000445	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—HRAS—skin cancer	3.69e-06	0.000434	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—KRAS—skin cancer	3.68e-06	0.000433	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—HRAS—skin cancer	3.62e-06	0.000426	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—IL6—skin cancer	3.53e-06	0.000416	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.51e-06	0.000413	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—ERCC2—skin cancer	3.38e-06	0.000397	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—TERT—skin cancer	3.37e-06	0.000397	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—HRAS—skin cancer	3.26e-06	0.000383	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.2e-06	0.000376	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—HRAS—skin cancer	3.13e-06	0.000368	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—IL6—skin cancer	3.12e-06	0.000367	CbGpPWpGaD
Trabectedin—SRC—Disease—PTGS2—skin cancer	3.08e-06	0.000362	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—PTGS2—skin cancer	2.71e-06	0.000319	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—ENO2—skin cancer	2.7e-06	0.000317	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—BRAF—skin cancer	2.67e-06	0.000314	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—ERCC2—skin cancer	2.61e-06	0.000307	CbGpPWpGaD
Trabectedin—SRC—Immune System—NRAS—skin cancer	2.59e-06	0.000305	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—ERCC2—skin cancer	2.4e-06	0.000282	CbGpPWpGaD
Trabectedin—SRC—Disease—NRAS—skin cancer	2.4e-06	0.000282	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—ERCC2—skin cancer	2.38e-06	0.00028	CbGpPWpGaD
Trabectedin—SRC—Immune System—KRAS—skin cancer	2.23e-06	0.000263	CbGpPWpGaD
Trabectedin—SRC—Disease—KRAS—skin cancer	2.06e-06	0.000243	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—PTGS2—skin cancer	2.03e-06	0.000238	CbGpPWpGaD
Trabectedin—SRC—Immune System—HRAS—skin cancer	1.9e-06	0.000223	CbGpPWpGaD
Trabectedin—SRC—Immune System—IL6—skin cancer	1.82e-06	0.000214	CbGpPWpGaD
Trabectedin—SRC—Disease—HRAS—skin cancer	1.75e-06	0.000206	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—NRAS—skin cancer	1.68e-06	0.000197	CbGpPWpGaD
Trabectedin—SRC—Disease—IL6—skin cancer	1.68e-06	0.000197	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—ERCC2—skin cancer	1.57e-06	0.000184	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PTGS2—skin cancer	1.56e-06	0.000184	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—KRAS—skin cancer	1.44e-06	0.00017	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PTGS2—skin cancer	1.44e-06	0.000169	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PTGS2—skin cancer	1.43e-06	0.000168	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—TP53—skin cancer	1.28e-06	0.000151	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—HRAS—skin cancer	1.23e-06	0.000144	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—IL6—skin cancer	1.17e-06	0.000138	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PTGS2—skin cancer	9.4e-07	0.000111	CbGpPWpGaD
